See more : Grupo Rotoplas S.A.B. de C.V. (AGUA.MX) Income Statement Analysis – Financial Results
Complete financial analysis of Amicus Therapeutics, Inc. (FOLD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amicus Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SMU S.A. (SMU.SN) Income Statement Analysis – Financial Results
- Fairchem Organics Limited (FAIRCHEMOR.NS) Income Statement Analysis – Financial Results
- Algoma Steel Group Inc. (ASTL) Income Statement Analysis – Financial Results
- China State Construction Development Holdings Limited (0830.HK) Income Statement Analysis – Financial Results
- Plank Ventures Ltd. (PLNK.CN) Income Statement Analysis – Financial Results
Amicus Therapeutics, Inc. (FOLD)
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 399.36M | 329.23M | 305.51M | 260.89M | 182.24M | 91.25M | 36.93M | 4.96M | 0.00 | 1.22M | 363.00K | 18.41M | 21.43M | 922.00K | 64.36M | 14.97M | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 37.33M | 38.60M | 34.47M | 31.04M | 21.96M | 14.40M | 6.24M | 833.00K | 1.83M | 0.00 | 13.49M | 20.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 362.03M | 290.63M | 271.05M | 229.84M | 160.27M | 76.84M | 30.69M | 4.13M | -1.83M | 1.22M | -13.13M | -1.97M | 21.43M | 922.00K | 64.36M | 14.97M | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 90.65% | 88.28% | 88.72% | 88.10% | 87.95% | 84.21% | 83.11% | 83.20% | 0.00% | 100.00% | -3,616.80% | -10.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 152.38M | 276.68M | 272.05M | 308.44M | 286.38M | 270.90M | 149.31M | 104.79M | 76.94M | 47.62M | 41.94M | 50.27M | 50.86M | 39.04M | 48.08M | 37.76M | 31.07M | 33.63M | 13.65M | 0.00 | 4.43M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.20M | 0.00 | 71.15M | 47.27M | 20.72M | 18.89M | 19.36M | 19.88M | 15.66M | 19.97M | 19.67M | 15.28M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 275.27M | 213.04M | 192.71M | 156.41M | 169.86M | 127.20M | 88.67M | 71.15M | 47.27M | 20.72M | 18.89M | 19.36M | 19.88M | 15.66M | 19.97M | 19.67M | 15.28M | 12.28M | 6.88M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 5.34M | 6.21M | 8.85M | 4.78M | -5.63M | 6.01M | -4.79M | -80.00K | -77.00K | 1.72M | 21.00K | 1.59M | 2.06M | 2.13M | 1.49M | 1.24M | 0.00 | 0.00 | -8.81M | 0.00 |
| Operating Expenses | 427.65M | 495.06M | 470.97M | 473.70M | 461.01M | 402.32M | 241.57M | 179.19M | 126.05M | 69.89M | 62.56M | 71.34M | 72.32M | 56.76M | 70.19M | 58.92M | 47.59M | 46.86M | 20.83M | -8.81M | 6.60M |
| Cost & Expenses | 472.85M | 533.66M | 505.43M | 504.74M | 482.98M | 416.72M | 247.81M | 180.02M | 126.05M | 69.89M | 62.56M | 71.34M | 72.32M | 56.76M | 70.19M | 58.92M | 47.59M | 46.86M | 20.83M | -8.81M | 6.60M |
| Interest Income | 7.08M | 3.02M | 509.00K | 3.23M | 10.25M | 10.46M | 4.10M | 1.60M | 929.00K | 223.00K | 174.00K | 316.00K | 160.00K | 156.00K | 997.00K | 4.82M | 0.00 | 1.99M | 609.52K | 0.00 | 5.00K |
| Interest Expense | 50.15M | 37.12M | 32.47M | 22.43M | 18.87M | 22.40M | 17.24M | 5.40M | 1.58M | 1.48M | 46.00K | 89.00K | 148.00K | 260.00K | 278.00K | 218.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.87M | 5.34M | 6.21M | 8.85M | 4.78M | 4.22M | 3.59M | 3.24M | 1.83M | 1.55M | 1.72M | 1.71M | 1.59M | 2.06M | 2.13M | 1.49M | 1.24M | 952.45K | 667.38K | 0.00 | 132.00K |
| EBITDA | -92.08M | -199.58M | -202.87M | -242.98M | -332.26M | -322.47M | -428.29M | -195.14M | -128.71M | -67.01M | -61.38M | -50.24M | -46.54M | -53.76M | -4.16M | -37.64M | -44.57M | -44.70M | -20.20M | -8.81M | -6.47M |
| EBITDA Ratio | -23.06% | -58.28% | -64.19% | -89.14% | -180.52% | -346.79% | -533.94% | -3,529.85% | 0.00% | -5,471.49% | -16,611.57% | -276.41% | -229.27% | -5,816.05% | -4.19% | -283.71% | -2,489.85% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -73.49M | -204.43M | -199.92M | -243.85M | -300.74M | -328.78M | -441.99M | -181.89M | -130.44M | -68.70M | -64.18M | -52.93M | -50.89M | -55.84M | -7.35M | -43.96M | -45.81M | -46.86M | -20.83M | -8.81M | -6.60M |
| Operating Income Ratio | -18.40% | -62.09% | -65.44% | -93.47% | -165.03% | -360.32% | -1,196.82% | -3,668.62% | 0.00% | -5,612.83% | -17,680.72% | -287.50% | -237.41% | -6,056.18% | -11.42% | -293.69% | -2,567.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -76.61M | -37.61M | -41.63M | -30.40M | -55.17M | -23.61M | -7.14M | -21.89M | -6.07M | -1.34M | 1.04M | 901.00K | 2.85M | -237.00K | 783.00K | 4.60M | 4.64M | 514.36K | 247.27K | 0.00 | -168.00K |
| Income Before Tax | -150.10M | -242.04M | -241.55M | -274.25M | -355.91M | -349.09M | -449.12M | -203.78M | -132.12M | -70.04M | -63.15M | -52.03M | -48.04M | -56.08M | -6.57M | -39.36M | -41.17M | -46.34M | -20.58M | 0.00 | -6.77M |
| Income Before Tax Ratio | -37.59% | -73.52% | -79.06% | -105.12% | -195.30% | -382.58% | -1,216.14% | -4,110.15% | 0.00% | -5,722.14% | -17,395.32% | -282.60% | -224.13% | -6,081.89% | -10.20% | -262.95% | -2,307.57% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.48M | -5.47M | 8.91M | 2.60M | 478.00K | -94.00K | -165.12M | -3.74M | 1.50M | -1.11M | -3.51M | -3.25M | -3.63M | -1.14M | 278.00K | 0.00 | 351.00K | -514.36K | -611.80K | 8.81M | 0.00 |
| Net Income | -151.58M | -236.57M | -250.46M | -276.85M | -356.39M | -349.00M | -284.00M | -200.04M | -132.12M | -68.93M | -59.63M | -48.79M | -44.41M | -54.94M | -6.57M | -39.36M | -41.17M | -46.34M | -19.97M | -8.81M | -6.77M |
| Net Income Ratio | -37.96% | -71.85% | -81.98% | -106.12% | -195.56% | -382.48% | -769.03% | -4,034.73% | 0.00% | -5,631.21% | -16,427.82% | -264.98% | -207.20% | -5,958.35% | -10.20% | -262.95% | -2,307.57% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | -1.88 | -1.85 | -1.49 | -1.20 | -0.93 | -1.16 | -1.07 | -1.28 | -1.98 | -0.29 | -1.75 | -3.11 | -62.97 | -48.69 | -28.64 | -22.01 |
| EPS Diluted | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | -1.88 | -1.85 | -1.49 | -1.20 | -0.93 | -1.16 | -1.07 | -1.28 | -1.98 | -0.29 | -1.75 | -3.11 | -62.97 | -48.69 | -28.64 | -22.01 |
| Weighted Avg Shares Out | 295.16M | 289.06M | 271.42M | 258.87M | 240.42M | 185.79M | 153.36M | 134.40M | 109.92M | 74.44M | 51.29M | 45.57M | 34.57M | 27.73M | 22.62M | 22.49M | 13.24M | 735.97K | 410.22K | 307.54K | 307.54K |
| Weighted Avg Shares Out (Dil) | 295.16M | 289.06M | 271.42M | 258.87M | 240.42M | 185.79M | 153.36M | 134.40M | 109.92M | 74.44M | 51.29M | 45.57M | 34.57M | 27.73M | 22.62M | 22.49M | 13.24M | 735.97K | 410.22K | 307.54K | 307.54K |
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates?
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
Amicus stock gains on reaching a licensing deal with Teva, which ends their Galafold patent lawsuit.
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Amicus Therapeutics, Inc. (FOLD) is looking like an interesting pick, as it just reached a key level of support. FOLD's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a...
How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44%
The consensus price target hints at a 43.4% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
On Thursday, Amicus Therapeutics FOLD announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. TEVA.
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual Congress of the World Muscle Society being held October...
'Boring' Amicus Therapeutics Is Making Progress
Amicus Therapeutics is making steady progress towards promised profitability, driven by the continued growth of Galafold and the launch of Pombiliti+Opfolda. The "beat-and-raise" guidance profile is missing this year and could partially explain the lack of the year-to-date share price...
3 'Repeatable' Biotech Trades
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call...
Source: https://incomestatements.info
Category: Stock Reports